KZIAライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (22 5月 2024 @ 05:00):

Stats
本日の出来高	44 505.00
平均出来高	467 487
時価総額	6.66M
EPS	$0 ( 2024-03-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.760
ATR14	$0.00600 (2.13%)

Insider Trading

Date	Person	Action	Amount	type
2013-11-04	Austin Josiah T	Sell	25 400	Sponsored ADRs, each convertible into 25 ordinary shares
2013-11-05	Austin Josiah T	Sell	23 922	Sponsored ADRs, each convertible into 25 ordinary shares
2013-10-25	Austin Josiah T	Sell	62 591	Sponsored ADRs, each convertible into 25 ordinary shares
2013-10-28	Austin Josiah T	Sell	37 409	Sponsored ADRs, each convertible into 25 ordinary shares
2013-10-29	Austin Josiah T	Sell	1 100	Sponsored ADRs, each convertible into 25 ordinary shares

INSIDER POWER
0.00
Last 100 transactions
Buy: 5 568 614 \| Sell: 243 947

ボリューム相関

長: -0.55 (weak negative)

短: -0.84 (strong negative)

Signal:(54.233) Neutral

Kazia Therapeutics 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Kazia Therapeutics 相関 - 通貨/商品

-0.15
( neutral )

-0.12
( neutral )

0.00
( neutral )

0.12
( neutral )

Kazia Therapeutics 財務諸表

Annual	2023
収益:	$555.00
総利益:	$555.00 (100.00 %)
EPS:	$-1.120

FY	2023
収益:	$555.00
総利益:	$555.00 (100.00 %)
EPS:	$-1.120

FY	2022
収益:	$25.00
総利益:	$25.00 (100.00 %)
EPS:	$-1.860

FY	2021
収益:	$15.18M
総利益:	$0.00 (0.00 %)
EPS:	$-0.716

Financial Reports:

No articles found.

Kazia Therapeutics Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Kazia Therapeutics

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.